Karyopharm Therapeutics Financials
| KPTI Stock | USD 4.65 0.32 7.39% |
Karyopharm | Build AI portfolio with Karyopharm Stock |
Karyopharm Therapeutics Stock Summary
Karyopharm Therapeutics competes with X4 Pharmaceuticals, Hookipa Pharma, Mereo BioPharma, Acumen Pharmaceuticals, and CytomX Therapeutics. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US48576U2050 |
| CUSIP | 48576U106 48576U205 |
| Location | Massachusetts; U.S.A |
| Business Address | 85 Wells Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.karyopharm.com |
| Phone | 617 658 0600 |
| Currency | USD - US Dollar |
Karyopharm Therapeutics Key Financial Ratios
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.45 | ||||
| Target Price | 29.25 | ||||
| Number Of Employees | 279 | ||||
| Beta | 0.23 |
Karyopharm Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Karyopharm Therapeutics's current stock value. Our valuation model uses many indicators to compare Karyopharm Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Karyopharm Therapeutics competition to find correlations between indicators driving Karyopharm Therapeutics's intrinsic value. More Info.Karyopharm Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Karyopharm Therapeutics' earnings, one of the primary drivers of an investment's value.Karyopharm Therapeutics Systematic Risk
Karyopharm Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Karyopharm Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was two with a total number of output elements of fifty-nine. The Beta measures systematic risk based on how returns on Karyopharm Therapeutics correlated with the market. If Beta is less than 0 Karyopharm Therapeutics generally moves in the opposite direction as compared to the market. If Karyopharm Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Karyopharm Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Karyopharm Therapeutics is generally in the same direction as the market. If Beta > 1 Karyopharm Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Karyopharm Therapeutics Financials
What exactly are Karyopharm Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Karyopharm Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Karyopharm Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics investors may use each financial statement separately, they are all related. The changes in Karyopharm Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karyopharm Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Karyopharm Therapeutics Thematic Clasifications
Karyopharm Therapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
| Cancer Fighters | View |
Karyopharm Therapeutics June 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Karyopharm Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Karyopharm Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Karyopharm Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Karyopharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Karyopharm Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.21 | |||
| Information Ratio | 0.0116 | |||
| Maximum Drawdown | 34.69 | |||
| Value At Risk | (10.10) | |||
| Potential Upside | 11.67 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |